Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC

January 29, 2021 Auto Bot Advanced, Amgen, Clinical Trials, NSCLC, P-II, Report, results, Sotorasib, Study 0

Shots:

  • The P-II cohort of the CodeBreaK 100 clinical study involves assessing Sotorasib (AMG 510, 960mg, qd) in 126 patients with KRAS G12C-mutated advanced NSCLC. The findings will be presented at the IASLC 2020 WCLC
  • Results: @median follow up of 12.2 mos., ORR (37.1%); DCR (80.6%); mDoR (10 mos.), PFS (6.8 mos.). Median tumor shrinkage among all responders was 60% and complete responses observed
  • Sotorasib is 1st KRAS G12C Inhibitor to enter the clinic and is being studied in the broadest clinical program exploring 10 combinations with global sites spanning five continents

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fierce Pharma

The post Amgen Report Results of Sotorasib in P-II Study for KRAS G12C-Mutated Advanced NSCLC first appeared on PharmaShots.